Abstract:Background: Diabetic nephropathy (DN) is the leading cause of end-stage failure of the kidneys; however, its pathogenesis remains unknown. This study assessed the expression of complement components in the kidneys of rats with type 2 DN to investigate their role in DN.Methods: A rat model of type 2 DN was induced by a high-fat diet combined with low-dose streptozotocin. Blood glucose, fasting insulin levels, insulin resistance index, and 24-h urinary albumin excretion (UAE) were measured. Renal tissue morphological features were observed. The mesangial index and arteriosclerosis index were calculated. Immunohistochemistry and western blot were used to measure the expression of complement components in the kidneys.Results: The kidney weight: body weight (mg/g) ratio in the DN group was significantly greater than those in the control and diabetes mellitus (DM) groups. The arteriosclerosis index, mesangial index, and tube area percentage in the DN group were significantly higher than those in the control and DM groups, but these parameters did not significantly differ between the control and DM groups. The expression of the complement components C1q, mannose-binding lectin (MBL), mannan-binding lectin-associated serine protease (MASP)-2, B factor, C3, and C5b-9 in the DN group was significantly higher than that in the control and DM groups but did not significantly differ between the control and DM groups. Most of the complement components were mainly expressed at the renal tubular site. Correlation analysis showed that 24-h UAE were positively correlated with C1q, MBL, MASP-2, B factor, and C5b-9 expression. MI was positively correlated with MBL, B factor, C3, and C5b-9 expression. AI was positively correlated with C1q, MBL, MASP-2, and B factor expression.Conclusion: Complement components including C1q, MBL, MASP-2, B factor, C3, and C5b-9, were highly expressed in the kidneys of type 2 diabetic rats with DN. Most of the complement components were mainly expressed in the renal tubules. High expression of complement components was found to be associated with the progress of DN. Our study suggests that complement system activation is a progressive factor in type 2 diabetic nephropathy. Inhibition of pathological complement activation may be a promising therapeutic strategy for DN.

Urinary and Tissue Immunohistochemical Expression of Complement Activation Products among Diabetic Nephropathy Patients in Different Stages

Detection of TNF-α,IL-18 and ADPN in Type 2 Diabetic Patients with Nephropathy

Complement Activation in Patients with Diabetic Nephropathy.

Clinical Significance of Determination of Serum Cystatin C,lipoprotein (α) and High Sensitivity C-reactive Protein in Type 2 Diabetic Patients with Early Renal Impairment.

Complement Deposition on Renal Histopathology of Patients with Diabetic Nephropathy.

High Expression of Complement Components in the Kidneys of Type 2 Diabetic Rats With Diabetic Nephropathy

Capillary Deposition of Complement C4d and C3d in Chinese Renal Allograft Biopsies.

Therapeutic Potential of Targeting Complement C5a Receptors in Diabetic Kidney Disease

Potential Role and Excretion Level of Urinary Transferrin, KIM-1, RBP, MCP-1 and NGAL Markers in Diabetic Nephropathy

Complement Activation Products in the Circulation and Urine of Primary Membranous Nephropathy.

Urinary C3dg and C5b-9 indicate active immune disease in human membranous nephropathy

Complement Activation Contributes to the Injury and Outcome of Kidney in Human Anti-glomerular Basement Membrane Disease

Levels of Inflammatory Cytokines in Type 2 Diabetes Patients with Different Urinary Albumin Excretion Rates and Their Correlation with Clinical Variables

Study on the Clinical Significance of Serum Cystatin C in Different Stage of Renal Impairment in Type 2 Diabetic Patients

C3c deposition predicts worse renal outcomes in patients with biopsy‐proven diabetic kidney disease in type 2 diabetes mellitus

Evaluation of urinary biomarkers for coronary artery disease, diabetes, and diabetic kidney disease

Deficiency of C3a receptor attenuates the development of diabetic nephropathy.

Evaluating new biomarkers for diabetic nephropathy: Role of α2-macroglobulin, podocalyxin, α-L-fucosidase, retinol-binding protein-4, and cystatin C

The diagnostic value of immunohistochemical staining of the interstitial vascular C4d complement in membranous nephropathy

Potential role of serum copeptin among smoker T2DM patients with emphasis to ACE I/D gene polymorphism predicting DN

Investigation of the Mechanism of Complement System in Diabetic Nephropathy via Bioinformatics Analysis